Population Health Research Institute, David Braley Cardiac, Vascular, and Stroke Research Institute, 237 Barton Street East, Hamilton, ON L8L 2X2, Canada; Thrombosis and Atherosclerosis Research Institute, David Braley Cardiac, Vascular, and Stroke Research Institute, 237 Barton Street East, Hamilton, ON L8L 2X2, Canada; Department of Pathology and Molecular Medicine, McMaster University, Michael G. DeGroote School of Medicine, 1280 Main Street West, Hamilton ON L8S 4K1, Canada; Institute of Social and Preventative Medicine, Lausanne University Hospital, Lausanne, 1010, Switzerland; Swiss Institute of Bioinformatics, Lausanne, 1015, Switzerland.
Population Health Research Institute, David Braley Cardiac, Vascular, and Stroke Research Institute, 237 Barton Street East, Hamilton, ON L8L 2X2, Canada; Department of Clinical Epidemiology and Biostatistics, McMaster University, 1280 Main Street West, Hamilton ON L8S 4K1, Canada.
Am J Hum Genet. 2020 Mar 5;106(3):303-314. doi: 10.1016/j.ajhg.2020.01.016. Epub 2020 Feb 13.
Disease risk varies significantly between ethnic groups, however, the clinical significance and implications of these observations are poorly understood. Investigating ethnic differences within the human proteome may shed light on the impact of ancestry on disease risk. We used admixture mapping to explore the impact of genetic ancestry on 237 cardiometabolic biomarkers in 2,216 Latin Americans within the Outcomes Reduction with an Initial Glargine Intervention (ORIGIN) study. We developed a variance component model in order to determine the proportion of variance explained by inter-ancestry differences, and we applied it to the biomarker panel. Multivariable linear regression was used to identify and localize genetic loci affecting biomarker variability between ethnicities. Variance component analysis revealed that 5% of biomarkers were significantly impacted by genetic admixture (p < 0.05/237), including C-peptide, apolipoprotein-E, and intercellular adhesion molecule 1. We also identified 46 regional associations across 40 different biomarkers (p < 1.13 × 10). An independent analysis revealed that 34 of these 46 regions were associated at genome-wide significance (p < 5 × 10) with their respective biomarker in either Europeans or Latin populations. Additional analyses revealed that an admixture mapping signal associated with increased C-peptide levels was also associated with an increase in diabetes risk (odds ratio [OR] = 6.07 per SD, 95% confidence interval [CI] 1.44 to 25.56, p = 0.01) and surrogate measures of insulin resistance. Our results demonstrate the impact of ancestry on biomarker levels, suggesting that some of the observed differences in disease prevalence have a biological basis, and that reference intervals for those biomarkers should be tailored to ancestry. Specifically, our results point to a strong role of ancestry in insulin resistance and diabetes risk.
疾病风险在不同种族之间存在显著差异,但这些观察结果的临床意义和影响仍知之甚少。研究人类蛋白质组中的种族差异可能有助于了解祖先对疾病风险的影响。我们使用混合映射方法来探讨遗传背景对 2216 名拉丁美洲人 237 种心血管代谢生物标志物的影响,这些人参加了 Outcomes Reduction with an Initial Glargine Intervention(ORIGIN)研究。我们开发了一个方差分量模型,以确定种族间差异解释的方差比例,并将其应用于生物标志物面板。多变量线性回归用于确定和定位影响不同种族间生物标志物变异的遗传基因座。方差分量分析表明,5%的生物标志物受到遗传混合的显著影响(p<0.05/237),包括 C 肽、载脂蛋白-E 和细胞间黏附分子 1。我们还在 40 种不同的生物标志物中发现了 46 个区域关联(p<1.13×10)。独立分析表明,在欧洲人和拉丁人群中,这些 46 个区域中的 34 个与各自的生物标志物在全基因组水平上具有显著相关性(p<5×10)。进一步的分析表明,与 C 肽水平升高相关的混合映射信号也与糖尿病风险增加相关(优势比[OR]为每标准差 6.07,95%置信区间[CI]为 1.44 至 25.56,p=0.01)和胰岛素抵抗的替代测量值。我们的研究结果表明,遗传背景对生物标志物水平有影响,这表明一些观察到的疾病患病率差异具有生物学基础,并且这些生物标志物的参考区间应该根据遗传背景进行调整。具体而言,我们的结果表明,遗传背景在胰岛素抵抗和糖尿病风险中起着重要作用。